Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gyre Therapeutics ( (GYRE) ) has shared an update.
On August 18, 2025, Gyre Therapeutics appointed Dan Weng, M.D., as a Class II director to its Board of Directors. Dr. Weng, who has extensive experience in managing global clinical trials and has held leadership roles in various contract research organizations, is expected to bring strategic insight and regulatory expertise to Gyre as it expands its commercial reach and advances its multinational pipeline.
The most recent analyst rating on (GYRE) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Gyre Therapeutics stock, see the GYRE Stock Forecast page.
Spark’s Take on GYRE Stock
According to Spark, TipRanks’ AI Analyst, GYRE is a Neutral.
Gyre Therapeutics’ overall stock score reflects a stable financial performance with strong gross margins but challenges in profitability and cash flow. Technical indicators suggest a bearish trend, and the stock appears overvalued based on its high P/E ratio. Positive corporate events, including leadership changes and successful trial results, provide a boost to the outlook.
To see Spark’s full report on GYRE stock, click here.
More about Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company based in San Diego, CA, focusing on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the United States. The company leverages its expertise in mechanistic studies and clinical trials for liver fibrosis and has a broad pipeline in China through its controlling interest in Gyre Pharmaceuticals, which includes products like ETUARY® and development programs for F573, F528, and F230.
Average Trading Volume: 217,387
Technical Sentiment Signal: Sell
Current Market Cap: $683.9M
See more data about GYRE stock on TipRanks’ Stock Analysis page.